Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-25-096925
Filing Date
2025-04-25
Accepted
2025-04-25 16:25:44
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A d901958ddefa14a.htm DEFA14A 11102
2 GRAPHIC g901958dsp002.jpg GRAPHIC 324113
3 GRAPHIC g901958dsp003.jpg GRAPHIC 188875
  Complete submission text file 0001193125-25-096925.txt   713323
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36332 | Film No.: 25874507
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)